Precision Medicine

CA Representative Reintroduces Precision Medicine Access Bill | HealthIT Analytics | 10/11/2019

Precision Medicine News CA Representative Reintroduces Precision Medicine Access Bill The precision medicine bill would expand the use of genetic and genomic testing for pediatric patients. Source: Thinkstock By October 11, 2019 - California representative Eric Swalwell recently reintroduced the bipartisan Advancing Access to Precision Medicine Act , which aims to increase the use of genomic and genetic testing for pediatric patients with rare diseases. The act would pilot-test whether Medicaid …

UB Biorepository is bringing the power of precision medicine to Western New York | 10/11/2019

… biological specimens that will allow UB and its research and industry partners to harness the discoveries that ultimately benefit patients. The UB Biorepository strengthens the ability of researchers in academia and industry to advance precision medicine by developing new drugs and diagnostic tools targeted to specific disorders and even individual patients. “The biorepository is important to UB for many reasons,” said Venu Govindaraju, PhD, vice president for research and economic …

Follow Precision Medicine:    

Global Precision Medicine Market Size to Worth US$ 84 Bn by 2026 | 10/11/2019

The global precision medicine market is expected to reach the market value of around US$ 84 billion by 2026 and is anticipated to grow at a CAGR of around 10% in terms of revenue during the forecast period 2019 – 2026. Free Download Sample Report Pages for Better [email protected] https://www.acumenresearchandconsulting.com/request-sample/1588 Recent progress in cancer treatment is strongly linked to genomic medicine among all disease classifications. Comprehension of …

Indiana University Employs Cloud Computing, AI for Precision Medicine | HIT Infrastructure | 10/10/2019

Cloud News Indiana University Employs Cloud Computing, AI for Precision Medicine Indiana University (IU) is using cloud computing and artificial intelligence (AI) to advance its precision medicine initiatives. Source: Thinkstock By October 09, 2019 - Indiana University (IU) is using cloud computing and artificial intelligence (AI) to advance its precision medicine initiatives. IU is employing these technologies to target certain cancers, such as multiple myeloma, triple-negative breast cancer, and pediatric …

Precision Medicine Gets A Boost From Congress | Forbes | 10/10/2019

… time from symptom onset to an accurate diagnosis, which averages 4.8 years. Last month, together with several colleagues in the House, Representative Eric Swalwell of California reintroduced a bipartisan bill called Advancing Access to Precision Medicine Act . The legislation had originally been proposed in January 2018, and is aimed at promoting the use of genetic and genomic testing to improve healthcare delivery. Specifically, the bill is designed to improve patient …

Read_EPUB Genomic and Precision Medicine Foundations, Translation, and Implementation book ‘[Full_Books]’ 824 | 10/10/2019

Genomic and Precision Medicine Foundations, Translation, and Implementation book Download at = https://downloadpdfkulucky.blogspot.com/0128006811 Genomic and Precision Medicine Foundations, Translation, and Implementation book pdf download, Genomic and Precision Medicine Foundations, Translation, and Implementation book audiobook download, Genomic and Precision Medicine Foundations, Translation, and Implementation book read online, Genomic and Precision Medicine Foundations, Translation, and Implementation book epub, Genomic and Precision Medicine Foundations, Translation, and Implementation book pdf full ebook, Genomic …

Homecare Homebase confirmed the successful launch of HCHB Exchange | PRWeb | 10/9/2019

… The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, MHK (formerly MedHOK—Medical House of Knowledge) and Hearst Health Ventures ( http://www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth or LinkedIn @Hearst-Health. Share article on social media or email: View article via …

Allegheny Health Network Announces Transition of Prominent Leaders to Critical New Roles | PRWeb | 10/9/2019

… new cancer units at West Penn Hospital and five new comprehensive community cancer centers across the western Pennsylvania region. Dr. Parda has been a pioneer throughout his career in the fields of radiation oncology, precision medicine and multidisciplinary cancer care coordination, and he has been instrumental in cultivating AHN’s unique clinical and research partnership with Johns Hopkins Kimmel Cancer Center. He joined AGH in 1998, and like Dr. Cohen, has …

Novigenix Receives Reimbursement Coverage for Colox® in Switzerland | Business & Finance | manchestertimes.com | Business Wire | 10/9/2019

LAUSANNE, Switzerland–(BUSINESS WIRE)–Oct 9, 2019– Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance provider in Switzerland, has started coverage for Colox ®, a liquid biopsy test for early detection of colorectal cancer. In Switzerland, over 4,500 new cases of colorectal cancer are diagnosed every year. Since market introduction, more than …

Lenovo and Intel Power Computational Research at the Flatiron Institute | Business Wire | 10/9/2019

RALEIGH, N.C.–(BUSINESS WIRE)–Oct 9, 2019– Lenovo and Intel today revealed how their collaboration on joint technology solutions that accelerate the convergence of high-performance computing (HPC) and artificial intelligence (AI) is helping scientists at the Flatiron Institute solve scientific challenges in entirely new ways. The Flatiron Institute, located in New York City, is the internal research division of the Simons Foundation, whose mission is to advance the frontiers …

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer | PR Newswire | 10/9/2019

BOSTON and SHANGHAI Oncologie, a biopharmaceutical company using an innovative precision medicine platform to develop next-generation oncology therapeutics, announced today the enrollment of the first patient in its global Phase 2 study of bavituximab in combination with Merck’s (known outside of the U.S. as MSD), anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer. Oncologie is collaborating with MSD in this clinical study to …

BlueBee Establishes Data Center in Mainland China, Expanding Global Coverage for Its Genomics Data Platform | PR Newswire | 10/9/2019

RIJSWIJK, Netherlands , Oct. 9, BlueBee, a global bioinformatics solutions provider, has extended data operations to mainland China to serve genomic data processing needs in compliance with The Chinese Ministry of Health and Technology. This strategic move will serve existing and new BlueBee customers who integrate bioinformatic data solutions with their analytical instruments, omics assay technology, or high-throughput laboratory services. BlueBee expects that this investment will result in mutual growth …

Wearables and Connected Devices Labor Market Growing at a CAGR of 29-30 Percent, Says Beroe Inc | PR Newswire | 10/9/2019

RALEIGH, North Carolina , Oct. 9, The global market for wearables and connected devices is currently estimated to be worth $14.5 billion and is expected to reach a value of $18.9 billion by 2020, according to Beroe Inc., a procurement intelligence firm. Approximately 600 million wearables are expected to share data online globally by 2020, the market is driven by the massive health data benefits offered by wearables. North America and …

ImaginAb To Present At Innovation Showcase 2019 Hosted By The Lundquist Institute | PR Newswire | 10/9/2019

LOS ANGELES , Oct. 9, ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, today announces that its Chief Executive Officer, Ian Wilson , will present an update on ImaginaAb and progress achieved with the CD8 ImmunoPET minibody at the upcoming Innovation Showcase 2019 on Monday, October 14, 2019 , at The Lundquist Institute (formerly LA BioMed), 1124 West Carson Street, Torrance, CA. The Innovation Showcase is a prestigious forum where academic institutions …

Evotec And Celmatix Enter Into Strategic Collaboration | 10/9/2019

… CLINICAL PROGRAMMES FOR HIGH UNMET MEDICAL NEED CONDITIONS FOR WOMEN HAMBURG, GERMANY and NEW YORK, NY / ACCESSWIRE / October 9, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, today announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility. The …

Overexpression Of hsa-miR-664a-3p Is Associated With Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Via Targeting FHL1 | 10/9/2019

Peer reviewers approved by Dr Melinda Thomas Peer reviewer comments 3 Editor who approved publication: Prof. Dr. Chunxue Bai Shan Zhong, 1, 2 Chengshui Chen, 3 Naijia Liu, 2 Li Yang, 3 Zhangli Hu, 2 Pengfei Duan, 1 Diquan Shuai, 2 Qingying Zhang, 1 Yun Wang 2 1 Department of Preventive Medicine, Shantou University Medical College, Shantou, Guangdong 515041, People’s Republic of China; 2 Center for Research and Technology of …

How this metastatic breast cancer patient became her own best advocate for personalized treatment | 10/9/2019

BPT) - There are few things more frightening than an advanced cancer diagnosis. Karen Peterson knows this better than most. A 54-year-old single mother from Harlem, she is a cancer survivor three times over. But she almost wasn’t. A childhood cancer survivor, in 2015 Peterson was diagnosed with triple negative breast cancer, an aggressive and difficult-to-treat cancer with a high likelihood of coming back. To treat it …

Genomind Supports New Reimbursement Initiatives and Patient Access to Mental Health Pharmacogenomic Tests with PGx Report Focused on Anxiety and Depression | Business Wire | 10/8/2019

KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–Oct 8, 2019– Genomind ®, the leading mental health company bringing precision medicine into mainstream mental health treatment, today announced that it has created a variation of its industry-leading mental health pharmacogenomic (PGx) report that focuses solely on depression and anxiety. Genomind Professional PGx Express™ will now offer its CORE Anxiety and Depression Report™, a 15-gene panel specifically designed for the pharmacogenomics of …

Computational Biology Postdoctoral Fellow | Nature | 10/8/2019

San Antonio, TX, United States Posted about 13 hours ago Expires on December 06, 2019 A motivated Postdoctoral fellow in the area of computational biology is sought for a position in the Division of Bioinformatics and Computational Biology ( CBBI ) in the Greehey Children’s Cancer Research Institute. The focus of research is to develop and apply deep learning algorithms that effectively model drug response process by integrating multiple types of big …

IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial | PR Newswire | 10/8/2019

SOUTH SAN FRANCISCO , Oct. 8, IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its first patient with cutaneous melanoma harboring a GNAQ or GNA11 ( GNAQ/11 ) mutation, a key milestone for evaluating Protein Kinase C (PKC) inhibitor IDE196 in solid tumors outside of metastatic uveal melanoma (MUM) as part of IDEAYA’s ongoing Phase …

NIH

NIH Research Centers Will Advance Precision Medicine for Alzheimer’s | HealthIT Analytics | 10/3/2019

Precision Medicine News NIH Research Centers Will Advance Precision Medicine for Alzheimer’s The two new centers will diversify and improve the Alzheimer’s drug development pipeline, contributing to precision medicine advancements for the disease. Source: Thinkstock By October 03, 2019 - The National Institutes on Aging (NIA), part of NIH, have launched two new research centers designed to advance precision medicine for Alzheimer’s disease and reinvigorate the drug development pipeline. The Alzheimer …

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center | 10/1/2019

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center 27-Sep-2019 12:05 AM EDT Interview with Alan Palkowitz, director of Indiana University’s new Alzheimer’s disease drug discovery center … Dementia , Drug Discovery , Pharmaceutical Science , Biomedical Engineering , Immunology , precision health , Precision Medicine , precision medicine approach , personalized medicine , National Institute On Aging , National Institutes of Health , Aging , Mental Health , Drug Development , novel drug target , Drug Target …

National Institutes of Health

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center | 10/1/2019

Precision Medicine , precision medicine approach , personalized medicine , National Institute On Aging , National Institutes of Health , Aging , Mental Health , Drug Development , novel drug target , Drug Target , Immune System , drug pipeline INDIANAPOLIS – Indiana University School of Medicine has been awarded a grant expected to total $36 million over five years from the National Institutes of Health to launch a drug discovery center to accelerate the development of promising treatments for Alzheimer’s disease …

North America’s $1.58 Bn Cancer Tissue Diagnostics Market to 2027: Analysis & Forecasts by Test Type & Country - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 9/27/2019

Precision Medicine Initiative (PMI) is a research endeavor, which involves the National Institutes of Health (NIH) and various other research centers. The initiative has been created to analyze a person’s genetics, environment, and lifestyle to determine a suitable approach for the prevention or treatment of disease. The PMI was launched during the fiscal year 2016, approximately $130 million were allocated to NIH to establish a large-scale research participant group …

Biotech

Biotechs Strive to Combat Rising Cancer Mortality Rates … | MarketWatch | 10/7/2019

… first cell-based gene therapy approved in the U.S. and is priced at USD 475,000 for a course of treatment. Biotechnology companies are now tasked with developing effective treatments but also at an affordable cost … support the design and development of better treatments through enhanced precision medicine. The IGCS is committed to addressing this critical issue. Dr. Thomas Conrads, a nationally acclaimed protein chemist, is the Senior Director of Women’s …

Food and Drug Administration

Biotechs Strive to Combat Rising Cancer Mortality Rates … | MarketWatch | 10/7/2019

… average patient, it is difficult to obtain the monetary funds necessary to pay for effective treatments. For instance, the U.S. Food and Drug Administration approved tisagenlecleucel to treat patients with acute lymphoblastic leukemia, a drug … support the design and development of better treatments through enhanced precision medicine. The IGCS is committed to addressing this critical issue. Dr. Thomas Conrads, a nationally acclaimed protein chemist, is the Senior Director of Women’s …

Clinical Data

Homecare Homebase confirmed the successful launch of HCHB Exchange | PRWeb | 10/9/2019

… national providers. HCHB Exchange users enjoy instant access to Surescript’s Record Locator and Exchange service, which enables easy exchange of clinical data among more than 100,000 clinicians nationwide, plus more than 600,000 care providers connected … http://www.hearsthealth.com ). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth or LinkedIn @Hearst-Health. Share article on social media or email: View …

Eli Lilly and Company’s (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript) | Seeking Alpha | 10/2/2019

… for new medicines along with new indications for our launched products. Those themes of innovations, expansion, business development and impactful clinical data are all part of our call today as we share highlights from our … discontinuation rate serves as a reminder of the benefits of precision medicine. In summary, on Slide 16, among the largest cohort of RET altered cancer patients ever treated on a single clinical trial, selpercatinib showed …

Digital Health

Ariel Precision Medicine Receives Prestigious Tech 50 Award from Pittsburgh Technology Council | Globe Newswire | 10/3/2019

October 03, 2019 08:00 ET Source: Ariel Precision Medicine Pittsburgh, Oct. 03, Ariel Precision Medicine, Inc., a privately held integrated genomics and digital health company developing innovative solutions for complex chronic disease, announced that the Pittsburgh Technology Council has named Ariel Innovator of the Year in the Life Sciences category. Following their nomination, the council evaluated Ariel’s business accomplishments as well as their technology advancements, including the company’s flagship product …

Ariel Precision Medicine Receives Prestigious Tech 50 Award from Pittsburgh Technology Council | Financial Buzz | 10/3/2019

Pittsburgh, Ariel Precision Medicine, Inc., a privately held integrated genomics and digital health company developing innovative solutions for complex chronic disease, announced that the Pittsburgh Technology Council has named Ariel Innovator of the Year in the Life Sciences category. Following their nomination, the council evaluated Ariel’s business accomplishments as well as their technology advancements, including the company’s flagship product, ADVANCE®, a cloud-based clinical decision support tool designed to simplify …

Genomics

UB Biorepository is bringing the power of precision medicine to Western New York | 10/11/2019

… the discoveries that ultimately benefit patients. The UB Biorepository strengthens the ability of researchers in academia and industry to advance precision medicine by developing new drugs and diagnostic tools targeted to specific disorders and even … a hub for collaboration.” Part of the Buffalo Institute for Genomics and Data Analytics Funded by UB and New York State, the UB Biorepository is a critical part of the Buffalo Institute for Genomics and …

BlueBee Establishes Data Center in Mainland China, Expanding Global Coverage for Its Genomics Data Platform | PR Newswire | 10/9/2019

… BlueBee and its partner clients due to immediate demand from its existing customer base and projected growth of the Chinese genomics market. Many geographical regions require that personal health information (PHI), which includes genomics data … diagnostics, therapeutics, and research with a shared mission—to power precision medicine. BlueBee software solutions are available for deployment globally, including most recently—mainland China . To stay up to date with BlueBee, follow @bluebeegenomics on …

AMA

Genomind and DrChrono Expand Collaboration to Improve Mental Health Outcomes With Innovative Technology and Services | Business & Finance | heraldchronicle.com | Business Wire | 10/1/2019

… ago Save KING OF PRUSSIA, Pa. & SUNNYVALE, Calif.–(BUSINESS WIRE)–Oct 1, 2019– Genomind ®, a leading mental health company bringing precision medicine into mainstream mental health treatment, and DrChrono , a company enabling the medical practice … Council for Continuing Medical Education (ACCME) for 1.25 hours of AMA PRA Category 1 CME credits. Those interested are able to register for the CME course by contacting Genomind’s customer service at 877-895-8658 or . Daniel …

Pittsburgh Health Data Alliance looks to machine learning for patient care | ZDNet | 8/8/2019

The partnership with AWS will see the alliance use machine learning to advance innovation in areas such as cancer diagnostics, precision medicine, voice-enabled technologies, and medical imaging. Topic: Innovation The Pittsburgh Health Data Alliance (PHDA) has announced a machine learning research sponsorship from Amazon Web Services (AWS) that would see the alliance aim to advance innovation in areas such as cancer diagnostics, precision medicine, voice-enabled technologies, and medical …

Medical Research

Bioelectronics ‘jump-start’ the next wave of device therapeutics | 10/3/2019

How dual-career couples find fulfillment at work A number of themes currently dominate medical research headlines—for example gene therapy , gene silencing via siRNA, CRISPR and gene editing, immuno-oncology and the gut microbiome … Second, miniaturized electric stimulators have the potential to deliver true precision medicine. Consider patients with paralysis caused by CNS damage in a stroke or by traumatic brain injury; a bioelectronics therapeutics application to restore motor …

Visiongain Report Claims there is Huge Potential Within the $28bn Stem Cell Technologies and Applications Market | PR Newswire | 9/30/2019

… of Biotechnology Insception Biosciences Intellia Therapeutics IntelliCell Biosciences IPS Academia Japan Isar Medical Centre Israel Healthcare Venture Japan Institute of Biomedical Research. JCR Pharmaceuticals JingYuan Bio . Johnson & Johnson Kirby Institute Lifebank Cryogenics LifebankUSA LifeCord LifeMap … e-mail Sara Peerun on [email protected] Related reports: Global Precision Medicine Market Forecast 2019-2029 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Biobanking Market Forecasts 2019-2029 Global Graft versus Host Disease (GVHD) Market 2019-2029 …

National Cancer Institute

Allegheny Health Network Announces Transition of Prominent Leaders to Critical New Roles | PRWeb | 10/9/2019

… across the western Pennsylvania region. Dr. Parda has been a pioneer throughout his career in the fields of radiation oncology, precision medicine and multidisciplinary cancer care coordination, and he has been instrumental in cultivating AHN’s … at Georgetown University, with additional cancer research training at the National Cancer Institute and Memorial Sloan Kettering Cancer Center. He is board-certified in both internal medicine and radiation oncology. Under Dr. Parda’s leadership, AHN’s …

Healthcare Companies Seek Innovative Ways to Combat New Diseases | PR Newswire | 10/1/2019

… believed that immunotherapy drugs can effectively treat autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, according to the National Cancer Institute. And while immunotherapy is generally believed to be much safer than chemotherapy … in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.” Eli …

Pfizer

Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC) | PR Newswire | 10/2/2019

… development. NMS has an excellent track record of licensing innovative drugs to pharma/biotech companies, including Array (recently acquired by Pfizer), Ignyta (acquired by Roche) and Genentech. About Trovagene, Inc. Trovagene is a a clinical … clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in …

AstraZeneca/Merck’s Lynparza Positive in Prostate Cancer Study | Zacks | 10/1/2019

… detailed data from a phase III study evaluating the company’s and Merck’s ( MRK - Free Report ) PARP inhibitor, Lynparza, as a precision medicine for an advanced prostate cancer patient population, at the European Society of Medical … NHA) treatments like J&J’s ( JNJ - Free Report ) Zytiga and Pfizer ( PFE - Free Report ) /Astellas’ Xtandi which makes it a difficult-to-treat disease. Data from the study showed that Lynparza improved radiographic progression-free …

Novartis

ImaginAb To Present At Innovation Showcase 2019 Hosted By The Lundquist Institute | PR Newswire | 10/9/2019

… an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full … Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com . About CD8 ImmunoPET CD8 ImmunoPET minibody …

ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine | PR Newswire | 10/8/2019

… an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full … Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com . About CD8 ImmunoPET CD8 ImmunoPET minibody …

Thermo Fisher

$4.2 Billion NGS-Based RNA-Sequencing Markets - Global Forecast to 2024: Rapid Growth in Precision Medicine Driving Growth | PR Newswire | 10/7/2019

… conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; rapid growth in precision medicine are the key factors driving the growth of the NGS based RNA sequencing … Oxford Nanopore Technologies Perkinelmer Psmogen Qiagen Roche Takara HoldiNGS Inc. Thermo Fisher Scientific Zymo Research For more information about this report visit https://www.researchandmarkets.com/r/eg173j Research and Markets also offers Custom Research services providing …

North America’s $1.58 Bn Cancer Tissue Diagnostics Market to 2027: Analysis & Forecasts by Test Type & Country - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | Business Wire | 9/27/2019

… genetic mutations. In the US, attempts are made to integrate personalized medicine into healthcare practices. In the United States, the Precision Medicine Initiative (PMI) is a research endeavor, which involves the National Institutes of Health … the forecast period. Moreover, the companies namely, Agilent Technologies Inc., Thermo Fisher Scientific, Inc., Cancer Genetics Inc. and F. Hoffmann-La Roche Ltd. have received approvals in the cancer tissue diagnostics market. Some of the …

Merck

ImaginAb To Present At Innovation Showcase 2019 Hosted By The Lundquist Institute | PR Newswire | 10/9/2019

… an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full … for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group. For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com . About CD8 ImmunoPET …

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer | 10/9/2019

precision medicine platform to develop next-generation oncology therapeutics, announced today the enrollment of the first patient in its global Phase 2 study of bavituximab in combination with Merck ‘s (known outside of the U.S. as MSD), anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer. Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients …

Syapse

InsightRX Welcomes Two New Expert Specialists to Its Expanding Team | PR Newswire | 9/26/2019

SAN FRANCISCO – InsightRX , a pioneer in precision medicine, is pleased to announce the addition of Dunnie Norman as Senior Vice President of Sales, and Andro Hsu , PhD as Director of Marketing to their growing team … information technology, and the life sciences, including roles at GRAIL, Syapse, and 23andMe. In addition, he holds a PhD in molecular and cell biology from the University of California, Berkeley . To learn more about InsightRX …

Syapse Appoints Fletcher Payne as Chief Financial Officer | Globe Newswire | 9/10/2019

Life sciences veteran brings 25 years of experience leading the financial, commercial and business operations of growth-oriented, global healthcare and technology businesses September 10, 2019 08:00 ET Source: Syapse SAN FRANCISCO, Sept. 10, 2019 (GLOBE NEWSWIRE) – Syapse, a company accelerating precision medicine through insights derived from its global health system network, today announced that Fletcher Payne has been appointed Chief Financial Officer. In this role, Payne will build on …

Qiagen

Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound? | Zacks | 8/23/2019

… Equity Research Cancel Read More Hide Full Article It has been about a month since the last earnings report for Qiagen ( QGEN - Free Report ) . Shares have lost about 8.7% in that time frame, underperforming the … classes which are Molecular Diagnostics (that includes human healthcare including Precision Medicine and companion diagnostics) and Life Sciences (that includes Pharma and Academia/Applied Testing). Molecular diagnostics (representing 49% of net sales) revenues were up …

Global Nucleic Acid Isolation and Purification Industry | PR Newswire | 8/20/2019

… Danaher Corporation ( USA ); GE Healthcare ( USA ); Illumina, Inc. ( USA ); Merck KgaA ( Germany ); New England Biolabs, Inc. ( USA ); Promega Corporation ( USA ); Qiagen NV ( The Netherlands ); Roche Molecular Systems, Inc. ( Switzerland ); Takara Bio , Inc. ( Japan ); Thermo Fisher … by Region/Country: 2009 VS 2019 VS 2025 Table 19: Precision Medicine (Application) Sales Estimates and Forecasts in US$ Million by Region/Country for the Years 2018 through 2025 Table 20: Precision Medicine (Application) Analysis …

Siemens

FDA Clears Modules of AI-Rad Companion Chest CT From Siemens Healthineers | Business Wire | 9/26/2019

… Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT¹, an intelligent software assistant from Siemens Healthineers that brings artificial intelligence (AI) to computed tomography (CT). Representing the first intelligent … increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of …

Survey: Discomfort May Deter Large Number of Women From Obtaining Mammograms | Business & Finance | manchestertimes.com | Business Wire | 9/25/2019

MALVERN, Pa.–(BUSINESS WIRE)–Sep 25, 2019– Siemens Healthineers and HealthyWomen, the nation’s leading independent, nonprofit health information source for women, today announced results from a new national survey designed to deepen understanding on how … increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products …

GE Healthcare

Global Nucleic Acid Isolation and Purification Industry | PR Newswire | 8/20/2019

… Competitors identified in this market include, among others, Agilent Technologies, Inc. ( USA ); Bio-Rad Laboratories, Inc. ( USA ); Danaher Corporation ( USA ); GE Healthcare ( USA ); Illumina, Inc. ( USA ); Merck KgaA ( Germany ); New England Biolabs, Inc. ( USA ); Promega … by Region/Country: 2009 VS 2019 VS 2025 Table 19: Precision Medicine (Application) Sales Estimates and Forecasts in US$ Million by Region/Country for the Years 2018 through 2025 Table 20: Precision Medicine (Application) Analysis …

Avalon Forms A Colossal Partnership - Avalon GloboCare Corp. (NASDAQ:AVCO) | Seeking Alpha | 7/31/2019

precision medicine and diagnostics. For instance, the company recently inked a mega partnership with GE Healthcare ( GE ). In this research, I’ll present a fundamental analysis of Avalon while focusing on the latest partnership development. Figure 1: Avalon stock chart (Source: StockCharts ) About The Company As usual, I’ll deliver a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent …

Siemens Healthineers

FDA Clears Modules of AI-Rad Companion Chest CT From Siemens Healthineers | Business Wire | 9/26/2019

… Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT¹, an intelligent software assistant from Siemens Healthineers that brings artificial intelligence (AI) to computed tomography (CT). Representing the first intelligent … increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of …

FDA Clears Artis Icono Family of Angiography Systems from Siemens Healthineers | 9/18/2019

… interdisciplinary usage The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers. The Artis icono floor angiography system is a flexible, multi-axis option for … systems in the Artis icono family expand the reach of precision medicine. At its core, the Artis icono platform delivers the new OPTIQ image chain, which redesigns image processing for 2-D imaging, according to …

Amgen

Amgen Reports Second Quarter 2019 Financial Results | PR Newswire | 7/31/2019

THOUSAND OAKS, Calif. Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2019. Key results include: Total revenues decreased 3% to $5.9 billion in comparison to the second quarter of 2018 reflecting … a global collaboration that combines Intermountain’s internationally-recognized expertise in precision medicine and clinical care with deCODE’s world-class expertise in human population genetics and will involve the participation of up to half a million …

Pfizer, Syapse to mine real-world cancer data for insight into molecular testing strategies | FierceBiotech | 7/23/2019

Like Amgen and Roche before it, Pfizer has tapped Syapse to help provide precision medicine data gathering and real-world outcomes research for its work in cancer. But where those collaborations focused on improving drug development and care delivery, Syapse’s latest undertaking will home in on the factors influencing oncologists as they choose different molecular testing and therapy strategies for individual patients. “We look forward to working with Syapse and …

Ascension Ventures

OSF Ventures gathers $75 mln for sophomore fund | PE Hub | 7/25/2019

… invested in 15 companies and is preparing to close on investment in another. Additionally, investments in two venture capital funds – Ascension Ventures and LRV Health round out the initial OSF Ventures portfolio. “Our venture program … digital transformation, the deployment of advanced analytics and adoption of precision medicine platforms.”-Michelle Conger One example of a strategic investment includes Regroup, a Chicago-based start-up that provides telemedicine solutions to eradicate mental …

OSF Ventures Launches Second Venture Capital Fund | PR Newswire | 7/25/2019

… invested in 15 companies and is preparing to close on investment in another. Additionally, investments in two venture capital funds – Ascension Ventures and LRV Health round out the initial OSF Ventures portfolio. “Our venture program … digital transformation, the deployment of advanced analytics and adoption of precision medicine platforms.”- Michelle Conger One example of a strategic investment includes Regroup , a Chicago -based start-up that provides telemedicine solutions to eradicate mental …

Amgen Ventures

GNS Healthcare’s AI patient-matching platform nets $23M from Cigna Ventures, Amgen, Celgene | FierceBiotech | 7/17/2019

GNS Healthcare raised $23 million from the venture capital arms of drugmakers and health insurance companies to build out its artificial-intelligence-driven precision medicine platform. The company’s series D round was lead by Cigna Ventures and included additional backing from Amgen Ventures, Celgene, Echo Health Ventures and Alexandria Venture Investments as well as an investment from Gary Loveman, who previously served as president of Aetna’s consumer health division. By …

Cigna Ventures leads $23M funding round in precision medicine company GNS Healthcare | FierceHealthcare Payer | 7/9/2019

… precision medicine. GNS Healthcare has raised $23 million in a series D fundraising round led by Cigna Ventures, the corporate venture fund of global health service company Cigna. Joining the funding round were Amgen Ventures, Celgene, Echo Health Ventures and Alexandria Venture Investments, as well as former Caesar’s CEO and Aetna Division President Gary Loveman. GNS uses machine learning to effectively match the appropriate therapeutics, procedures and treatment intervention to …

Goldman Sachs

Eli Lilly and Company’s (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript) | Seeking Alpha | 10/2/2019

Eli Lilly and Company (NYSE: LLY ) Goldman Sachs 40th Annual Global Helathcare Conference October 2, 2019 9:00 AM ET Company Participants Kim Macko - Director, Investor Relations Anne White - President of Lilly Oncology Dan Skovronsky - President … discontinuation rate serves as a reminder of the benefits of precision medicine. In summary, on Slide 16, among the largest cohort of RET altered cancer patients ever treated on a single clinical trial, selpercatinib showed …

Agios Pharmaceuticals (NASDAQ:AGIO) Cut to “Sell” at Zacks Investment Research - Ticker Report | 9/19/2019

… reports. They currently have $40.00 price objective on the biopharmaceutical company’s stock. According to Zacks, “Agios’ newly approved wholly owned precision medicine Tibsovo has been performing steadily since its launch. The drug’s label expansion studies … Agios Pharmaceuticals in a research note on Friday, May 31st. Goldman Sachs Group reiterated a neutral rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, May …

GE Ventures

Amgen taps Syapse to infuse real-world data into its cancer clinical trial designs | FierceBiotech | 5/3/2019

Precision medicine company Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development. Together, Amgen and Syapse will … The San Francisco-based company’s previous backers include Ascension Ventures, GE Ventures and Intermountain Healthcare Innovation Fund. Syapse’s oncology software platform is designed to help healthcare providers offer precision medicine consistently, including through clinical trials …

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology | PR Newswire | 1/9/2018

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology Multi-year partnership to focus on product development and clinical delivery to bring precision medicine to more patients News provided by 06:00 ET … backed by investors including Social Capital, Safeguard Scientifics, Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures. Contact …

Morgan Stanley

Caris Life Sciences to Present at the 17th Annual Morgan Stanley Global Healthcare Conference | BioSpace | 9/10/2019

Caris Life Sciences to Present at the 17th Annual Morgan Stanley Global Healthcare Conference Published: Sep 10, 2019 IRVING, Texas , Sept. 10, 2019 /PRNewswire/ – Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian J. Brille , Vice Chairman of the Company, will present at the 17 th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019 , at …

Blueprint Medicines Corp (BPMC) CEO Jeffrey Albers on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/2/2019

… Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Group Charles Zhu - Guggenheim Marc Frahm - Cowen and Company David Lebowitz - Morgan Stanley Andrew Berens - SVB Leerink Michael Ulz - Robert W. Baird & Co. Arlinda Lee - Canaccord … First, we need to increase tumor mutation testing, to bring precision medicine to GIST patients especially those with PDGFRalpha, Exon 18 mutations that aren’t addressed by current therapies. Today, only 30% to 40% of GIST …

Merck Global Health Innovation

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology | PR Newswire | 1/9/2018

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology Multi-year partnership to focus on product development and clinical delivery to bring precision medicine to more patients News provided by 06:00 ET … Safeguard Scientifics, Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures. Contact …

Roche Venture Fund

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology | PR Newswire | 1/9/2018

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology Multi-year partnership to focus on product development and clinical delivery to bring precision medicine to more patients News provided by 06:00 ET … Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures. Contact …

Merck Global Health Innovation Fund

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology | PR Newswire | 1/9/2018

Syapse Enters Strategic Collaboration with Roche to Advance Precision Medicine in Oncology Multi-year partnership to focus on product development and clinical delivery to bring precision medicine to more patients News provided by 06:00 ET … Safeguard Scientifics, Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Merck Global Health Innovation Fund, Medidata Solutions, Roche Venture Fund, and Amgen Ventures. Contact …

Apple Tree Partners

Chinook secures funds for kidney disease treatments | 8/23/2019

Canada-based Chinook Therapeutics has received funds in a Series A round to support the development of precision medicines for treating kidney diseases. The company’s founding investor, Versant Venture, led the $65m financing round. Apple Tree Partners and Samsara BioCapital also participated in the round. Chinook Therapeutics plans to use the funds to bring many of its kidney disease programmes into clinical trials by 2021. The company’s platform is based …

Chinook Therapeutics bags $65M to bring precision medicine to the kidney | FierceBiotech | 8/22/2019

Apple Tree Partners and Samsara BioCapital to do so. The Vancouver, Canada-based biotech wants to do for kidney disease what precision medicine has done for cancer treatment. It will use that capital to push “several” precision medicines for rare kidney diseases into the clinic by 2021. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our …

Merrill Lynch

Myokardia (NASDAQ:MYOK), Sanofi (NYSE:SNY) - Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health | Benzinga | 8/28/2019

… Cardiology Congress Aug. 31-Sept. 4 in Paris. The South San Francisco, California-based biotech, founded in 2012, uses a precision medicine approach to discover and develop targeted therapies for serious and neglected rare cardiovascular … sales potential of $1.5 billion, according to Bank of America Merrill Lynch analyst Tazeen Ahmad. HCM results from the enlargement of heart muscle cells, causing the thickening of the walls of the ventricles, specifically the …

Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 7/24/2019

… Hooker - KeyBanc Patrick Donnelly - Goldman Sachs Alexa Desai - Ricky Goldwasser Bill Quirk - Piper Jaffray Derik de Bruin - Bank of America Merrill Lynch Matt Larew - William Blair Eric Coldwell - Baird Mark Massaro - Canaccord Genuity Operator Welcome … as a designated laboratory in the National Cancer Institute’s MATCH precision medicine trial. This is the largest of its kind. The trial seeks to provide better outcomes for rare cancer types for which there is …

HCA

Breakthrough Genomics & EpigeneticsRx Partner to Further Functional Genomic Analysis and Innovations for the Medical Industry | PRWeb | 8/24/2019

… within a medical setting,” states Deb Hubers, CEO of EpigeneticsRx. EpigeneticsRx’s platform is built on functional genomics, directed by licensed healthcare providers. The partnership capitalizes on EpigeneticsRx’s base of 25,000+ patients and 2,500+ healthcare professionals … actively working to innovate within the rapidly growing field of precision medicine. Dr. Kulvi Kaur, Chief Scientific Officer of EpigeneticsRx, adds “Functional genomics focuses on the interplay of the various genetic markers rather than focusing …

Tempus Expands Leadership Team With the Appointment of Joel Dudley, PhD, as Senior Vice President of Research | Globe Newswire | 8/22/2019

August 22, 2019 12:00 ET Source: Tempus CHICAGO, Aug. 22, 2019 (GLOBE NEWSWIRE) – Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the appointment … as the founding Director of the Institute for Next Generation Healthcare at ISMMS. “Joel has spent a significant portion of his career in one of the country’s leading hospitals, harnessing the power of data to …

Harvard Medical School

Invicro Appoints Dr. Evan Morris as Vice President of Scientific Imaging Research, New Haven | Business & Finance | manchestertimes.com | Business Wire | 9/16/2019

… from my earlier work on more basic questions in imaging and kinetic modeling.” Dr. Morris did his postdoctoral fellowship at Harvard Medical School after completing his MS and Ph.D. in Biomedical Engineer at Case Western … Clinical in 2017. Now as part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and …

Gene mutation, tissue location, signaling networks drive cancer incidence and severity | 9/11/2019

… Cancer Discovery , Cell Reports , and Cell Systems . “The unifying theme of these three papers is that the way we practice precision medicine today is not precise enough,” said principal investigator and author Kevin Haigis, PhD … explained Haigis, who is also Associate Professor of Medicine at Harvard Medical School. “Our new research shows that you simply cannot place all KRAS mutant cancers in the same basket - each allele is actually quite …

MD Anderson Cancer Center

Postdoctoral Fellowships in Experimental Cancer Biology, Genetics and Epigenetics | Nature | 8/13/2019

MD Anderson Cancer Center Texas, United States Posted about 33 minutes ago Expires on October 12, 2019 The University of Texas MD Anderson Cancer Center Science Park invites applications for postdoctoral fellowships in experimental cancer biology, genetics and epigenetics starting immediately. Using state-of-the-art gene-editing and functional genomics/proteomics techniques, we seek to identify genetic and epigenetic biomarkers for human disease precision medicine, synthetic lethal and resistance …

The Future of Direct-to-Consumer Genetics, Precision Medicine, Neuroscience, and Diagnostic Technology to Be Explored at the 71st AACC Annual Scientific Meeting | PR Newswire | 8/5/2019

… insights on a broad range of timely healthcare topics. Highlights of these include discussions exploring direct-to-consumer genetic testing, precision medicine’s progress to date, how genes shape the brain circuitry that defines human behavior … MD, DSc, of the University of Texas Health San Antonio MD Anderson Cancer Center, will examine how precision medicine identifies breast cancer patients who will respond to targeted therapeutics—including those unlikely to respond to …

UPMC

Out for Blood: Biomarkers Paving the Road to Personalized Medicine for Rheumatic Diseases | 9/18/2019

… noted Amr H. Sawalha, MD . “[This] will be a major advance and big leap towards personalized medicine in rheumatology.” Source: UPMC Children’s Hospital of Pittsburgh. One significant drawback is that the MBDA results can be … management.” Trailblazing With Anti-CCP Antibodies When it comes to precision medicine in rheumatology, the single greatest advance is the development of clinical anti-CCP lab tests, according to Silverman. “This test transitioned the shared …

Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update | Globe Newswire | 8/21/2019

… Aug. 19, Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients … into that country. Helomics announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. Helomics signed a collaborative research agreement with Pittsburgh …

Mayo Clinic

Allegheny Health Network Announces Transition of Prominent Leaders to Critical New Roles | PRWeb | 10/9/2019

… across the western Pennsylvania region. Dr. Parda has been a pioneer throughout his career in the fields of radiation oncology, precision medicine and multidisciplinary cancer care coordination, and he has been instrumental in cultivating AHN’s … the nation’s preeminent medical centers, including the Cleveland Clinic and Mayo Clinic, and is viewed as a leadership structure that promotes high-quality, high-value clinical care and exceptional patient experiences. “It’s been a privilege …

Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO | PR Newswire | 10/1/2019

… will be enrolled. The trial is being conducted at two prestigious cancer centers: USC Norris Comprehensive Cancer Center and The Mayo Clinic Arizona. About Onvansertib Onvansertib is a first-in-class, third-generation, oral and … clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in …

Intermountain Healthcare

Intermountain Healthcare Offering Genomic Innovation Grants for Research Projects That Will Lead to Advancements in Precision Medicine | 9/18/2019

Intermountain Healthcare Offering Genomic Innovation Grants for Research Projects That Will Lead to Advancements in Precision Medicine Salt Lake City, UT – ( ReleaseWire ) – 09/18/2019 –Intermountain Precision Genomics is working to boost research, innovation, and advancement in genomics research by awarding up to $200,000 for biomedical research projects that strive to help people live the healthiest lives possible. The awards, called Genomic Innovation Grants, provide opportunity for scientific collaboration and offer funding …

Intermountain Healthcare Offering Genomic Innovation Grants for Research Projects That Will Lead to Advancements in Precision Medicine | The Wapakoneta Daily News | 9/18/2019

Intermountain Healthcare’s mission to help people live the healthiest lives possible,” said David Jones, senior scientific program director for Intermountain Precision Genomics. “Genomic Innovation Grants combine our translational research services with innovative research ideas to champion new discovery and further precision medicine and its clinical application.” The grants will support biomedical research proposals that have potential for direct clinical application. Investigators with such proposals are encouraged to apply. Past recipients …

Memorial Sloan Kettering

Allegheny Health Network Announces Transition of Prominent Leaders to Critical New Roles | PRWeb | 10/9/2019

… across the western Pennsylvania region. Dr. Parda has been a pioneer throughout his career in the fields of radiation oncology, precision medicine and multidisciplinary cancer care coordination, and he has been instrumental in cultivating AHN’s … additional cancer research training at the National Cancer Institute and Memorial Sloan Kettering Cancer Center. He is board-certified in both internal medicine and radiation oncology. Under Dr. Parda’s leadership, AHN’s radiation oncology network has …

ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine | PR Newswire | 10/8/2019

… for CD8+ T cell accumulation within tumors. Lead author of the study, Neeta Pandit-Taskar , MD, Nuclear Medicine Physician at Memorial Sloan Kettering Cancer Center, said: “This novel imaging agent has the potential to non … into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used …

Memorial Sloan Kettering Cancer Center

Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center | PR Newswire | 7/22/2019

… July 22, Kazia Therapeutics Limited (ASX: KZA;NASDAQ: KZIA ), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use … approach to clinical research that is sometimes referred to as ‘precision medicine’ or ‘personalized medicine’, in which treatments are carefully targeted to those patients most likely to benefit. It is expected that the trial will …

Managing Breast Cancer in 2015 - The ASCO Post | 5/10/2019

… breast cancer expert and ASCO past president Larry Norton, MD , Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center in New York. Reinvention of Clinical Trials Please tell the … potential reinvention of clinical trials due to the advent of precision medicine: that is, defining a particular target, developing an intervention to hit that target, and then examining the results. Seeing responses in this setting …

Massachusetts General Hospital

Visiongain Report Claims there is Huge Potential Within the $28bn Stem Cell Technologies and Applications Market | PR Newswire | 9/30/2019

… Pharmaceuticals and Medical Devices Agency Karolinska Institute Korean Food and Drug Administration Korean MFDS (Ministry of Food and Drug Safety) Massachusetts General Hospital McMaster University Musculoskeletal Transplant Foundation (MTF) New York Heart Association NHS Blood … e-mail Sara Peerun on [email protected] Related reports: Global Precision Medicine Market Forecast 2019-2029 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029 Biobanking Market Forecasts 2019-2029 Global Graft versus Host Disease (GVHD) Market 2019-2029 …

Depression, Alzheimer’s Pathology Signs of Cognitive Decline | HealthIT Analytics | 8/12/2019

… in cognitively healthy adults, along with biological markers of Alzheimer’s, could trigger cognitive decline over time. 12, 2019 - Researchers from Massachusetts General Hospital (MGH) have found that mild or moderate depression together with brain amyloid … of cortical amyloid in unimpaired people. Dig Deeper NIH Recommends Precision Medicine Approach to Treat Alzheimer’s Researchers collected data over a seven-year period from 276 older adults. The team found that there was a …

Ascension

OSF Ventures gathers $75 mln for sophomore fund | PE Hub | 7/25/2019

… invested in 15 companies and is preparing to close on investment in another. Additionally, investments in two venture capital funds – Ascension Ventures and LRV Health round out the initial OSF Ventures portfolio. “Our venture program … digital transformation, the deployment of advanced analytics and adoption of precision medicine platforms.”-Michelle Conger One example of a strategic investment includes Regroup, a Chicago-based start-up that provides telemedicine solutions to eradicate mental …

OSF Ventures Launches Second Venture Capital Fund | PR Newswire | 7/25/2019

… invested in 15 companies and is preparing to close on investment in another. Additionally, investments in two venture capital funds – Ascension Ventures and LRV Health round out the initial OSF Ventures portfolio. “Our venture program … digital transformation, the deployment of advanced analytics and adoption of precision medicine platforms.”- Michelle Conger One example of a strategic investment includes Regroup , a Chicago -based start-up that provides telemedicine solutions to eradicate mental …

Cigna

Cigna Invests In GNS Healthcare Precision Medicine Venture : Investors : Venture Capital Post | 8/6/2019

Cigna joined the parade of health insurance companies and biotech giants backing GNS Healthcare, a technology firm applying machine learning to healthcare through precision medicine. GNS said Tuesday it has raised $23 million led by Cigna Ventures as the health insurer looks to more precisely “match therapeutics, procedures and care management interventions to individuals to drive personalized clinical care,” GNS and Cigna said in a statement. The Cigna investment fits …

GNS Healthcare’s AI patient-matching platform nets $23M from Cigna Ventures, Amgen, Celgene | FierceBiotech | 7/17/2019

GNS Healthcare raised $23 million from the venture capital arms of drugmakers and health insurance companies to build out its artificial-intelligence-driven precision medicine platform. The company’s series D round was lead by Cigna Ventures and included additional backing from Amgen Ventures, Celgene, Echo Health Ventures and Alexandria Venture Investments as well as an investment from Gary Loveman, who previously served as president of Aetna’s consumer health division. By …

Health Net

FDA partners with Syapse to study regulatory use of real-world evidence | Healthcare IT News | 8/15/2019

The precision medicine company will work with the U.S. to see how secure patient data can be better put to work oncology treatments. FDA partners with Syapse to study regulatory use of real-world evidence … Syapse says it will also engage oncologists in its Learning Health Network in joint outcomes research, enabling the use of real-world evidence by oncology care providers to inform care decisions and outcomes research; the …

FDA Cancer COE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE) | HIT Consultant | 8/14/2019

… address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine. Methods to Derive RWE From Multiple Sources including EHRs As part of this … direct collaboration efforts, Syapse will engage oncologists in its Learning Health Network in joint outcomes research. This work will support Syapse in enabling the use of RWE by oncology care providers to inform care decisions …

Aetna

GNS Healthcare’s AI patient-matching platform nets $23M from Cigna Ventures, Amgen, Celgene | FierceBiotech | 7/17/2019

GNS Healthcare raised $23 million from the venture capital arms of drugmakers and health insurance companies to build out its artificial-intelligence-driven precision medicine platform. The company’s series D round was lead by Cigna Ventures and included additional backing from Amgen Ventures, Celgene, Echo Health Ventures and Alexandria Venture Investments as well as an investment from Gary Loveman, who previously served as president of Aetna’s consumer health division. By …

Precision Medicine Company GNS Healthcare Secures $23 Million | 7/12/2019

Leading precision medicine company GNS Healthcare announced it raised $23 million in strategic funding led by Cigna Ventures GNS Healthcare — a leading precision medicine company — announced it raised $23 million in a strategic Series D funding led by Cigna Ventures (a wholly-owned indirect subsidiary of Cigna Corporation). Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, and former Caesar’s CEO and Aetna Division President Gary Loveman also joined this …

UnitedHealthcare

Researchers Present New Data on the Utility of Genomind’s Mental Health Pharmacogenomic Testing at Upcoming Scientific Conferences | Business & Finance | heraldchronicle.com | Business Wire | 9/16/2019

KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–Sep 16, 2019– Genomind ®, a leading mental health company bringing precision medicine into mainstream mental health treatment, announced today that four abstracts in which Genomind’s pharmacogenomic test was utilized … months following testing. i The recent positive coverage decision from UnitedHealthcare cited multiple studies supporting the use of pharmacogenomic testing - including Genomind’s test - in certain patients with depression and anxiety. Genomind expects to provide additional …

Intervention Insights Welcomes Lee Newcomer, M.D. to Its Board of Directors | PR Newswire | 5/28/2019

BOSTON , May 28, Intervention Insights announces the appointment of Dr. Lee Newcomer , former UnitedHealthcare executive and Medical Director for Cigna Healthcare, to its Board of Directors to support the growth of its distinct, precision medicine platform Trapelo . Trapelo is the first-of-its-kind, real-time decision-support, order-management and results-reporting solution that aligns the interests of oncologists, labs, and payers as they navigate the complex field of …

Ken Tarkoff

Syapse Appoints Fletcher Payne as Chief Financial Officer | Benzinga | 9/10/2019

SAN FRANCISCO, Syapse, a company accelerating precision medicine through insights derived from its global health system network, today announced that Fletcher Payne has been appointed Chief Financial Officer. In this role, Payne will build on … at this exciting time of expansion for the company,” said Ken Tarkoff, CEO, Syapse. “Fletcher brings a deep understanding of the life sciences industry to Syapse and a proven track record of successful financial leadership …

Syapse Appoints Fletcher Payne as Chief Financial Officer | Financial Buzz | 9/10/2019

SAN FRANCISCO, Syapse, a company accelerating precision medicine through insights derived from its global health system network, today announced that Fletcher Payne has been appointed Chief Financial Officer. In this role, Payne will build on … at this exciting time of expansion for the company,” said Ken Tarkoff, CEO, Syapse. “Fletcher brings a deep understanding of the life sciences industry to Syapse and a proven track record of successful financial leadership …

Fred Hutchinson

Post-Doctoral Research Fellow, Kemp Laboratory of Functional Precision Medicine | Nature | 9/24/2019

Posted about 10 hours ago Expires on November 22, 2019 Overview Cures Start Here . At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV / AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune …

Kronos Bio Expands Scientific Advisory Board with Addition of Roger D. Kornberg, Ph.D. | Business & Finance | manchestertimes.com | Business Wire | 8/7/2019

Fred Hutchinson Cancer Research Center; Affiliate Professor of Biochemistry, University of Washington School of Medicine Angela Koehler, Ph.D. – Associate Professor, Department of Biological Engineering, Massachusetts Institute of Technology (MIT); Intramural Member, David H. Koch Institute for Integrative Cancer Research, MIT; Member, MIT Center for Cancer Precision Medicine; Associate Member, Broad Institute About Kronos Bio Kronos Bio, Inc. is dedicated to the discovery and development of first-in-class therapies that …

Mark Erlander

Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Business & Finance | heraldchronicle.com | PR Newswire | 8/26/2019

… as demonstrated by the immediate decrease in serum PSA levels in patients showing initial signs of resistance to Zytiga®,” said Mark Erlander, PhD, Chief Scientific Officer of Trovagene. “The inhibition of the PLK1 enzyme by … clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in …

Eric Dishman

Eric Dishman stepping down as director of NIH All of Us program to become chief innovation officer | FierceHealthcare | 8/28/2019

Aug 28, 2019 3:27pm The National Institutes of Health All of Us research program announced major leadership changes this week. (NIH) The National Institutes of Health’s (NIH’s) All of Us precision medicine research project announced leadership changes Tuesday as Eric Dishman will be stepping down from his role as director of the program. Dishman, who was tapped to lead the All of Us program in April 2016, said once a …

Thomas Adams

Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2 | PR Newswire | 9/19/2019

… 2 trial in AML is a significant step forward in the development of onvansertib for the treatment of AML,” said Thomas Adams , PhD, Chief Executive Officer and Chairman of Trovagene. “We are very pleased by … clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in …

Trovagene Announces Second Quarter 2019 Results and Highlights | PR Newswire | 8/9/2019

… progress with our clinical development of onvansertib with three clinical trials actively enrolling patients and advancing as planned,” said Dr. Thomas Adams , Chief Executive Officer and Chairman of Trovagene. “We initiated enrollment in our third … clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in …

Eric Topol

Natural Language Processing Supports Genetic Sequencing in Record Time | HealthIT Analytics | 4/25/2019

Precision Medicine News Natural Language Processing Supports Genetic Sequencing in Record Time Clinical natural language processing can drastically reduce the time required to complete genetic sequencing for pediatric patients in intensive care. 25, 2019 - Machine … to rapidly and accurately analyze their whole genome sequence ” said Eric Topol, MD, Professor of Molecular Medicine at Scripps Research. In order to continue accelerating the availability of precision diagnostics for pediatric patients, Kingsmore and …

Healthcare Luminaries Brent James, Eric Topol and Timothy Zoph Join Health Catalyst as Strategic Advisors | PR Newswire | 1/16/2018

Healthcare Luminaries Brent James, Eric Topol and Timothy Zoph Join Health Catalyst as Strategic Advisors News provided by 07:55 ET Share this article SALT LAKE CITY , Jan. 16, 2018 /PRNewswire/ – Health Catalyst , a leader in … Institutes of Health to lead a significant part of the Precision Medicine Initiative, a one million American prospective research program. He is the author of two bestselling books on the future of medicine: The Creative …

Bill Welch

Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 | PR Newswire | 11/13/2017

… evaluate dose and scheduling, and preliminary anti-leukemic activity News provided by 08:00 SAN DIEGO Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of its clinical trial site for its … potential activity in both hematologic and solid tumor cancers,” said Bill Welch , Chief Executive Officer of Trovagene. “We are excited to have Virginia Cancer Specialists as our first clinical trial site ready to screen and …

David Spetzler

Caris Life Sciences Receives FDA Breakthrough Device Designation for MI Transcriptome™ Companion Diagnostic Test | PR Newswire | 5/3/2019

IRVING, Texas , May 3, Caris Life Sciences®, a leading innovator in molecular science focused on precision medicine, today announced that the U.S. (FDA) has granted Breakthrough Device designation for the company’s MI Transcriptome™ companion diagnostic … as the best method to detect clinically relevant fusions,” said David Spetzler , MS, MBA, PhD, President and Chief Scientific Officer of Caris. “MI Transcriptome ™ CDx, which is enabled by Whole Transcriptome Sequencing, provides information on …

Caris Life Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference | PR Newswire | 1/2/2018

Caris Life Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference News provided by 08:30 ET Share this article IRVING, Texas , Jan. Caris Life Sciences ® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that David D. Halbert , Chairman and Chief Executive Officer, and David Spetzler , M.S., Ph.D., M.B.A., President and Chief Scientific Officer, will present at the 36 th Annual …

Razelle Kurzrock

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology | Business Wire | 5/17/2019

… by the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Rapidly changing landscape of Precision Medicine in Japan, Tokyo Medical and Dental University National Cancer Grid of India – Earthshots … Dana Farber Cancer Institute, USA “ Lifestyle-based Prevention Strategies”. Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “ Innovation in Clinical Trials: WINTHER trial”, first study pioneered by the WIN Consortium ( ) , that showed that …

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology | Business & Finance | heraldchronicle.com | Business Wire | 5/17/2019

… by the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Rapidly changing landscape of Precision Medicine in Japan, Tokyo Medical and Dental University National Cancer Grid of India – Earthshots … Dana Farber Cancer Institute, USA “ Lifestyle-based Prevention Strategies”. Dr. Razelle Kurzrock, MD, University of California, San Diego, USA, “ Innovation in Clinical Trials: WINTHER trial”, first study pioneered by the WIN Consortium ( ), that showed that …

Gregory Tranah

Research: Using ‘big data’ to help understand Multiple Sclerosis | Globe Newswire | 7/16/2019

… up with DNAnexus—a biomedical informatics and data management company. The collaboration with DNAnexus may help to accelerate Sutter’s MS precision medicine research by making it easier for clinician-researchers to analyze clinical and genetic … patient-reported outcomes, and blood samples for whole exome sequencing. Gregory Tranah, Ph.D ., Director of Sutter’s Center for Precision Medicine, Dr. Cooper, and other Sutter researchers will study patients’ clinical data and blood samples in …

Sutter, UPMC, DNAnexus partner on MS sequencing study | Healthcare Dive | 4/17/2019

… impact the treatment and outcomes of people living with multiple sclerosis, or MS. Under the arrangement, Sutter Health’s Center for Precision Medicine will input de-identified clinico-genomic datasets from over 3,000 patients in DNAnexus … bioinformatics tools to better understand our clinically meaningful ‘big data,’” Gregory Tranah, director of the Sutter Health Center for Precision Medicine, said in a statement . “This is an important step to advance precision medicine efforts …